A New Nanoparticle Is Designed to Target the Cells for Extremely Effective Anti-Inflammatory Treatment

A New Nanoparticle Is Designed to Target the Cells for Extremely Effective Anti-Inflammatory Treatme ...

Carole Bourquin's electron micrograph reveals the porous nature of the silica nanoparticles. These pores are large enough to allow the entry of a large number ofNSA molecules. Here, the NSA is released and can stop the inflammation process.

A group from UNIGE and LMU has developed a transport nanoparticle that would make an anti-inflammatory medicine much more effective and less toxic.

How can a medication be delivered exactly where it is needed, while minimizing the danger of side effects? Using nanoparticles to encapsulate a drug to protect it and the body until it reaches its intended dosage is increasingly studied. Furthermore, the researchers used an in vitro screening technique, which reduced the necessity for animal testing.

Inflammation is an essential physiological reaction of the body to defend itself against pathogens, such as bacteria. When it becomes a chronic condition, such as in cancers, autoimmune diseases, or certain viral infections, it can be problematic, as it becomes a condition, such as when high doses are required, and disastrous side effects are frequent.

Necrosulfonamide (NSA) is a new drug that inhibits the release of several key pro-inflammatory mediators, thus posing a promising step in reducing certain types of inflammation. However, it travels poorly in the bloodstream and may affect many cell types, triggering potentially harmful effects.

'This is why this protein isn't yet available as a medicine,' says Gaby Palmer, a professor in the UNIGE Faculty of Medicine's research unit. 'Using a nanoparticle as a transport vessel would mitigate these difficulties by delivering the medication directly into macrophages to combat inflammatory overactivation where it starts.'

'We used an in vitro screening technique we developed a few years ago on human and mouse cells,' says Carole Bourquin, a professor at the UNIGE's Faculties of Science (Institute of Pharmaceutical Sciences of Western Switzerland) and Medicine. 'Our experiment was a precursor to clinical studies on humans.'

'The first was less effective in cell uptake behavior, while the second was counterproductive,' says Bart Boersma, a doctoral student in Carole Bourquin's laboratory.

'The porous silica nanoparticle, on the other hand, met all the criteria: it was completely biodegradable, it was the right size to be swallowed by macrophages, and it was able to absorb the medication into its many pores without releasing it too early,' said the researchers. The researchers then applied the same technique to the nanoparticles, but with no greater benefit than silica nanoparticles alone.

'Here, they carry a very different medicine that inhibits the immune system,' says Carole Bourquin. 'In the pharmaceutical industry, these mesoporous silica nanoparticles demonstrate a promising synergistic.'

Bart Boersma, Karin Möller, Viola Puddinu, Sébastien Fauteux-Daniel, Gaby Palmer, and Thomas Bein, Journal of Controlled Release, 13 October 2022, DOI: 10.1016/j.jconrel.2022.09.063

You may also like: